The 2026 tau imaging news adds a new brain-scan option to Alzheimer's workups, but it does not replace clinical judgment. Memory clinic patients can avoid overreading headlines by treating tau PET as one piece alongside symptoms, amyloid results, and exam findings. Tau tangles are twisted clumps of tau protein inside brain cells, and tau PET makes their pattern visible on a scan.
Lantheus reported in its approval announcement that the FDA approved Tauklarify on Aug. 14, 2026 for tau imaging in adults with cognitive impairment evaluated for Alzheimer's disease. That approval expands the workup toolkit. It does not make tau PET a home test or a solo diagnosis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the FDA approve?
- Can the new scan find Alzheimer's changes earlier?
- Why can a positive tau scan mislead?
- Where do blood tests fit before PET?
- What should you ask your memory clinic team?
What did the FDA approve?
Tauklarify uses florquinitau F 18, formerly called MK-6240. It is a PET tracer that highlights tau tangles during an Alzheimer's evaluation. Use is limited to that setting. NeurologyLive reported in its approval coverage that approval rested on two blinded-read studies with more than 500 participants.
Positive agreement ran 68%-88% across five readers, while negative agreement ran 93%-99%. Interreader agreement was strong. The practical point is narrow. A negative read lowers concern for widespread cortical tau. A positive read still needs clinical and amyloid context before anyone names Alzheimer's disease.
Can the new scan find Alzheimer's changes earlier?
The HEAD study compared MK-6240 directly with flortaucipir in the same 682 people. It looked for early medial-temporal tau, the memory-area signal that often appears first. The University of Pittsburgh Health Sciences described in its HEAD study summary detection in 15% of cognitively unimpaired amyloid-positive people with MK-6240, versus 6% with flortaucipir. The same comparison found better separation of Alzheimer's-related impairment from non-Alzheimer's impairment.
NeurologyLive reports an AUC of 0.93 for MK-6240 versus 0.86 for flortaucipir. AUC measures discrimination, with 1.0 as perfect. Earlier visibility helps research and staging. It does not mean every early medial-temporal signal will progress, or that symptoms are already Alzheimer's dementia.
Why can a positive tau scan mislead?
The FDA labeling limits Tauklarify to Alzheimer's evaluation. NeurologyLive notes safety and effectiveness are not established for non-Alzheimer's tauopathies. A tau tracer cannot sort all dementias by itself. Off-target signal is a second limit.
UCSF autopsy-PET work, reported by MedicalXpress, found flortaucipir signal can reflect iron and MAO-B-related binding in non-Alzheimer's tauopathies. That creates a clear overreading risk when a bright scan is read alone. Clinical context guards against that error. Age, symptom pattern, medication exposures, amyloid status, and MRI or exam findings all shape meaning. A scan pattern that fits frontotemporal decline, parkinsonism, or vascular injury should prompt a different workup, not an Alzheimer's label.
Where do blood tests fit before PET?
Many clinics now screen blood for amyloid pathology first with FDA-cleared plasma p-tau217 tests. Fujirebio states on its product page that its Lumipulse ratio, first cleared May 16, 2025, showed 91.7% positive and 97.3% negative agreement with PET or spinal-fluid results. About 19.6% of results were indeterminate and needed PET or spinal-fluid follow-up. That sequence matters for patients. A clearly negative blood result may avoid PET.
A clearly positive result still needs a clinical diagnosis, treatment eligibility check, and counseling. An indeterminate result means pause, not panic, and ask what confirmatory test the clinic advises. Blood testing also frames tau PET. Amyloid-positive mild impairment plus a matching tau pattern strengthens an Alzheimer's explanation. Amyloid-negative impairment plus isolated tau signal should raise questions about other causes or off-target binding.
What should you ask your memory clinic team?
Bring the scan order, blood result, drug list, and symptom timeline to the visit. Ask how each result changed the leading diagnosis.
Ask what remains uncertain. Write down the answer in plain words before leaving. If the team would act the same without the scan, the headline mattered less than the visit did.
- Ask why tau PET was ordered: staging, unclear diagnosis, or treatment decision?
- Ask about amyloid status: is Alzheimer's pathology supported by blood, spinal fluid, or amyloid PET?
- Ask about alternatives: could vascular disease, sleep apnea, depression, medications, or another dementia better fit?
- Ask about the read: where is tau located, how confident is the read, and was off-target binding considered?
- Ask about next steps: repeat testing, referral, safety planning, trial options, or approved therapy criteria?
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: How Memory Clinic Patients Can Avoid Overreading the Headline
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: How Memory Clinic Patients Can Avoid Overreading the Headline
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How Memory Clinic Patients Can Avoid Overreading the Headline
